300723 一品红
已收盘 02-24 15:00:00
资讯
新帖
简况
一品红最新公告：子公司15个药品品种拟中选药品接续采购
证券之星 · 02-11
一品红最新公告：子公司15个药品品种拟中选药品接续采购
一品红：公司将按照《公司法》《企业会计准则》《上市公司监管指引第3号——上市公司现金分红》等相关法律法规和规范指引及《公司章程》等相关规定，确定利润分配政策和利润分配计划
证券之星 · 02-11
一品红：公司将按照《公司法》《企业会计准则》《上市公司监管指引第3号——上市公司现金分红》等相关法律法规和规范指引及《公司章程》等相关规定，确定利润分配政策和利润分配计划
一品红：公司始终坚持医药创新和高品质药品研发
证券之星 · 02-11
一品红：公司始终坚持医药创新和高品质药品研发
股市必读：一品红（300723）2月2日董秘有最新回复
证券之星 · 02-03
股市必读：一品红（300723）2月2日董秘有最新回复
一品红（300723）披露回购公司股份进展公告，2月2日股价下跌2.08%
证券之星 · 02-02
一品红（300723）披露回购公司股份进展公告，2月2日股价下跌2.08%
一品红：截止至2026年1月31日，公司股东总户数30,475户
证券之星 · 02-02
一品红：截止至2026年1月31日，公司股东总户数30,475户
一品红最新公告：全资子公司获得阿仑膦酸钠口服溶液注册证书
证券之星 · 01-30
一品红最新公告：全资子公司获得阿仑膦酸钠口服溶液注册证书
一品红最新公告：全资子公司芩香清解口服液获得药物临床试验通知书
证券之星 · 01-28
一品红最新公告：全资子公司芩香清解口服液获得药物临床试验通知书
一品红：聚焦于儿童药和慢病药领域
证券之星 · 01-28
一品红：聚焦于儿童药和慢病药领域
股市必读：1月22日一品红现1笔大宗交易 机构净买入419.48万元
证券之星 · 01-23
股市必读：1月22日一品红现1笔大宗交易 机构净买入419.48万元
股市必读：一品红（300723）1月19日董秘有最新回复
证券之星 · 01-20
股市必读：一品红（300723）1月19日董秘有最新回复
1月15日一品红跌6.92%，广发医疗保健股票A基金重仓该股
证券之星 · 01-15
1月15日一品红跌6.92%，广发医疗保健股票A基金重仓该股
一品红最新公告：预计2025年净亏损3.13亿元—4.42亿元
证券之星 · 01-14
一品红最新公告：预计2025年净亏损3.13亿元—4.42亿元
股市必读：一品红（300723）1月12日董秘有最新回复
证券之星 · 01-13
股市必读：一品红（300723）1月12日董秘有最新回复
一品红：2024年员工持股计划持股5,116,105股
证券之星 · 01-12
一品红：2024年员工持股计划持股5,116,105股
一品红：2024年员工持股计划第一个解锁期解禁股票并未减持
证券之星 · 01-09
一品红：2024年员工持股计划第一个解锁期解禁股票并未减持
股市必读：一品红（300723）1月8日董秘有最新回复
证券之星 · 01-09
股市必读：一品红（300723）1月8日董秘有最新回复
一品红：布局分子胶领域投资分迪药业和达歌生物
证券之星 · 01-08
一品红：布局分子胶领域投资分迪药业和达歌生物
股市必读：一品红(300723)股东户数2.65万户，较上期增加30.22%
证券之星 · 01-07
股市必读：一品红(300723)股东户数2.65万户，较上期增加30.22%
一品红（300723）披露关于回购公司股份的进展公告，1月5日股价上涨6.83%
证券之星 · 01-05
一品红（300723）披露关于回购公司股份的进展公告，1月5日股价上涨6.83%
加载更多
公司概况
公司名称：
一品红药业集团股份有限公司
所属行业：
医药制造业
上市日期：
2017-11-16
主营业务：
一品红药业集团股份有限公司的主营业务是药品的研发、生产和销售。公司的主要产品是化学药(含原料药和制剂)、特色中成药等。公司曾先后获得中国化药研发综合实力百强企业、中国创新力医药企业100强和中国化药企业百强企业等荣誉称号，是广州生物医药产业链的链主企业。
发行价格：
17.05
{"stockData":{"symbol":"300723","market":"SZ","secType":"STK","nameCN":"一品红","latestPrice":32.83,"timestamp":1771916634000,"preClose":33.29,"halted":0,"volume":6265428,"delay":0,"changeRate":-0.0138,"floatShares":418000000,"shares":451999999,"eps":-0.9511,"marketStatus":"已收盘","change":-0.46,"latestTime":"02-24 15:00:00","open":33.68,"high":33.69,"low":32.75,"amount":207000000,"amplitude":0.0282,"askPrice":32.83,"askSize":14,"bidPrice":32.82,"bidSize":16,"shortable":0,"etf":0,"ttmEps":-0.9511,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1771983000000},"marketStatusCode":5,"adr":0,"adjPreClose":33.29,"symbolType":"stock","openAndCloseTimeList":[[1771896600000,1771903800000],[1771909200000,1771916400000]],"highLimit":36.62,"lowLimit":29.96,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":451692766,"isCdr":false,"pbRate":8.59,"roa":"--","roe":"--","epsLYR":-1.1956,"committee":0.278997,"marketValue":14829000000,"turnoverRate":0.015,"status":1,"floatMarketCap":13712000000},"requestUrl":"/m/hq/s/300723","defaultTab":"news","newsList":[{"id":"2610052935","title":"一品红最新公告：子公司15个药品品种拟中选药品接续采购","url":"https://stock-news.laohu8.com/highlight/detail?id=2610052935","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610052935?lang=zh_cn&edition=full","pubTime":"2026-02-11 18:49","pubTimestamp":1770806987,"startTime":"0","endTime":"0","summary":"一品红(300723.SZ)公告称，公司全资子公司广州一品红制药有限公司于近日参加了国家组织集采药品协议期满品种接续采购办公室组织的国家组织集采药品协议期满品种接续采购的投标工作。根据接续采购办公室于2月10日发布的《国家组织集采药品协议期满品种接续采购拟中选结果公示》，公司共计15个药品品种拟中选本次接续采购。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026021100031684.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300723"],"gpt_icon":0},{"id":"2610036346","title":"一品红：公司将按照《公司法》《企业会计准则》《上市公司监管指引第3号——上市公司现金分红》等相关法律法规和规范指引及《公司章程》等相关规定，确定利润分配政策和利润分配计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2610036346","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610036346?lang=zh_cn&edition=full","pubTime":"2026-02-11 08:54","pubTimestamp":1770771252,"startTime":"0","endTime":"0","summary":"证券之星消息，一品红(300723)02月10日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘您好！公司公告示交易Arthrosi股权2026Q1可获得现金交割约67亿人民币首付款，届时公司账上有大量现金。请问2026年有股票现金分红吗？一品红回复：尊敬的投资者您好，感谢您对公司的关注。公司将按照《公司法》《企业会计准则》《上市公司监管指引第3号——上市公司现金分红》等相关法律法规和规范指引及《公司章程》等相关规定，确定利润分配政策和利润分配计划。祝您投资愉快。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026021100005981.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300723"],"gpt_icon":0},{"id":"2610036826","title":"一品红：公司始终坚持医药创新和高品质药品研发","url":"https://stock-news.laohu8.com/highlight/detail?id=2610036826","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610036826?lang=zh_cn&edition=full","pubTime":"2026-02-11 08:54","pubTimestamp":1770771251,"startTime":"0","endTime":"0","summary":"证券之星消息，一品红(300723)02月10日在投资者关系平台上答复投资者关心的问题。投资者提问：请问第一季度出售疼风药股权，只占15%左右的股份也就是10亿人民币的资金到账，是否为了应对之前的五亿诉讼一品红回复：尊敬的投资者您好，感谢您对公司的关注。一品红是一家集药品研发、生产、销售为一体的创新型生物医药企业，聚焦于儿童药和慢病药领域。公司始终坚持医药创新和高品质药品研发。祝您投资愉快。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026021100005980.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300723","09939","BK1161","BK0239","159938","BK1515","BK1574"],"gpt_icon":0},{"id":"2608899433","title":"股市必读：一品红（300723）2月2日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2608899433","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608899433?lang=zh_cn&edition=full","pubTime":"2026-02-03 01:38","pubTimestamp":1770053892,"startTime":"0","endTime":"0","summary":"截至2026年2月2日收盘，一品红报收于32.95元，下跌2.08%，换手率1.53%，成交量6.38万手，成交额2.14亿元。截止至2026年1月31日，公司股东总户数30,475户。公司公告汇总关于回购公司股份的进展公告一品红药业集团股份有限公司于2025年12月15日召开董事会审议通过回购股份方案，拟使用自有及自筹资金以集中竞价方式回购公司股份，用于维护公司价值及股东权益。公司后续将根据市场情况继续实施回购，并履行信息披露义务。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020300001044.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300723","BK0239"],"gpt_icon":0},{"id":"2608867455","title":"一品红（300723）披露回购公司股份进展公告，2月2日股价下跌2.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2608867455","media":"证券之星","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608867455?lang=zh_cn&edition=full","pubTime":"2026-02-02 22:28","pubTimestamp":1770042502,"startTime":"0","endTime":"0","summary":"截至2026年2月2日收盘，一品红报收于32.95元，较前一交易日下跌2.08%，最新总市值为148.83亿元。近日，一品红药业集团股份有限公司发布《关于回购公司股份的进展公告》。公告显示，公司于2025年12月15日召开董事会审议通过回购股份方案，拟使用自有及自筹资金以集中竞价方式回购公司股份，用于维护公司价值及股东权益。公司后续将根据市场情况继续实施回购，并履行信息披露义务。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020200039324.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300723","BK0239"],"gpt_icon":0},{"id":"2608854371","title":"一品红：截止至2026年1月31日，公司股东总户数30,475户","url":"https://stock-news.laohu8.com/highlight/detail?id=2608854371","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608854371?lang=zh_cn&edition=full","pubTime":"2026-02-02 17:00","pubTimestamp":1770022842,"startTime":"0","endTime":"0","summary":"证券之星消息，一品红(300723)02月02日在投资者关系平台上答复投资者关心的问题。投资者提问：请问1月10日公司股东人数是多少？谢谢！一品红回复：尊敬的投资者您好，感谢您对公司的关注。截止至2026年1月31日，公司股东总户数30,475户。祝您投资愉快。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020200024012.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300723"],"gpt_icon":0},{"id":"2607902970","title":"一品红最新公告：全资子公司获得阿仑膦酸钠口服溶液注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2607902970","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607902970?lang=zh_cn&edition=full","pubTime":"2026-01-30 16:44","pubTimestamp":1769762683,"startTime":"0","endTime":"0","summary":"一品红(300723.SZ)公告称，公司全资子公司广州一品红制药有限公司近日收到国家药品监督管理局核准签发的阿仑膦酸钠口服溶液《药品注册证书》。该药品适应症为治疗绝经后妇女的骨质疏松症，以预防髋部和脊柱骨折（椎骨压缩性骨折）；以及治疗男性骨质疏松以增加骨量。此次获得注册证书标志着公司具备了在国内市场销售该药品的资格，将进一步丰富公司产品管线和产品品类，增强公司在慢病药领域的竞争力。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026013000028102.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300723","BK0239"],"gpt_icon":0},{"id":"2606790891","title":"一品红最新公告：全资子公司芩香清解口服液获得药物临床试验通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2606790891","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606790891?lang=zh_cn&edition=full","pubTime":"2026-01-28 18:50","pubTimestamp":1769597444,"startTime":"0","endTime":"0","summary":"一品红(300723.SZ)公告称，公司全资子公司一品红生物医药有限公司申报的芩香清解口服液获得国家药品监督管理局签发的药物临床试验批准通知书，同意开展用于成人急性上呼吸道感染表里俱热证的临床试验。芩香清解口服液从药物组成、临床疗效等方面具有独特优势，将用药人群扩展到成人能够解决未被满足的临床需求。该药物研发具有高科技、高风险、高附加值的特点，周期长、环节多，易受到诸多不可预测的因素影响。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012800035381.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300723","BK0239"],"gpt_icon":0},{"id":"2606779530","title":"一品红：聚焦于儿童药和慢病药领域","url":"https://stock-news.laohu8.com/highlight/detail?id=2606779530","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606779530?lang=zh_cn&edition=full","pubTime":"2026-01-28 16:12","pubTimestamp":1769587934,"startTime":"0","endTime":"0","summary":"证券之星消息，一品红(300723)01月28日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘，你好！贵公司在核苷类药物有哪些具体布局？一品红回复：尊敬的投资者您好，感谢您对公司的关注。一品红是一家集药品研发、生产、销售为一体的创新型生物医药企业，聚焦于儿童药和慢病药领域；目前，公司具备医药全产业链的研发运营管理能力，产品涵盖范围包括化学药（含制剂和原料药）、中（成）药等领域。祝您投资愉快。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012800025604.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300723"],"gpt_icon":0},{"id":"2605150514","title":"股市必读：1月22日一品红现1笔大宗交易 机构净买入419.48万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2605150514","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605150514?lang=zh_cn&edition=full","pubTime":"2026-01-23 01:00","pubTimestamp":1769101240,"startTime":"0","endTime":"0","summary":"截至2026年1月22日收盘，一品红报收于35.31元，下跌1.34%，换手率2.25%，成交量9.42万手，成交额3.33亿元。当日关注点来自交易信息汇总：1月22日主力资金净流出2965.61万元，散户资金净流入2430.83万元。大宗交易1月22日一品红现1笔大宗交易，机构净买入419.48万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012300000515.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300723"],"gpt_icon":0},{"id":"2604130444","title":"股市必读：一品红（300723）1月19日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2604130444","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604130444?lang=zh_cn&edition=full","pubTime":"2026-01-20 02:20","pubTimestamp":1768846820,"startTime":"0","endTime":"0","summary":"截至2026年1月19日收盘，一品红报收于36.96元，下跌2.38%，换手率2.66%，成交量11.11万手，成交额4.12亿元。交易信息汇总资金流向1月19日主力资金净流出507.03万元；游资资金净流入1297.22万元；散户资金净流出790.19万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012000000903.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300723","BK0239"],"gpt_icon":0},{"id":"2603167436","title":"1月15日一品红跌6.92%，广发医疗保健股票A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2603167436","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603167436?lang=zh_cn&edition=full","pubTime":"2026-01-15 15:41","pubTimestamp":1768462903,"startTime":"0","endTime":"0","summary":"证券之星消息，1月15日一品红跌6.92%，收盘报38.86元，换手率6.48%，成交量27.05万手，成交额10.77亿元。重仓一品红的前十大公募基金请见下表：该股最近90天内共有3家机构给出评级，买入评级2家，增持评级1家。根据2025基金Q3季报公募基金重仓股数据，重仓该股的公募基金共44家，其中持有数量最多的公募基金为广发基金的广发医疗保健股票A。广发医疗保健股票A目前规模为51.85亿元，最新净值1.9453，较上一交易日下跌1.52%，近一年上涨22.75%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011500020060.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300723"],"gpt_icon":0},{"id":"2603188736","title":"一品红最新公告：预计2025年净亏损3.13亿元—4.42亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2603188736","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603188736?lang=zh_cn&edition=full","pubTime":"2026-01-14 19:39","pubTimestamp":1768390789,"startTime":"0","endTime":"0","summary":"一品红(300723.SZ)发布业绩预告，预计2025年净利润亏损3.13亿元—4.42亿元，上年同期亏损5.4亿元。报告期，公司产品销售及毛利率水平有一定程度下降，加上公司广东瑞石创新原料药生产基地投入使用导致折旧摊销增加及研发持续投入，影响了公司经营业绩。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011400036293.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300723"],"gpt_icon":0},{"id":"2603408315","title":"股市必读：一品红（300723）1月12日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2603408315","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603408315?lang=zh_cn&edition=full","pubTime":"2026-01-13 01:38","pubTimestamp":1768239489,"startTime":"0","endTime":"0","summary":"截至2026年1月12日收盘，一品红报收于37.46元，上涨0.27%，换手率3.34%，成交量13.96万手，成交额5.16亿元。董秘最新回复投资者： 最近成交量萎缩，股价也前置不前，一般横盘久了，会继续下跌，贵公司后期还有什么可以支撑股价的措施吗董秘： 尊敬的投资者您好，感谢您对公司的关注。当日关注点来自交易信息汇总：1月12日主力资金净流出1712.07万元，散户资金净流入3886.42万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011300001413.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300723"],"gpt_icon":0},{"id":"2602979295","title":"一品红：2024年员工持股计划持股5,116,105股","url":"https://stock-news.laohu8.com/highlight/detail?id=2602979295","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602979295?lang=zh_cn&edition=full","pubTime":"2026-01-12 16:48","pubTimestamp":1768207701,"startTime":"0","endTime":"0","summary":"证券之星消息，一品红(300723)01月12日在投资者关系平台上答复投资者关心的问题。投资者提问：贵公司股权激励没有减持，那股本股东显示为什么2025年9月30号退出前10大流通股？一品红回复：尊敬的投资者您好，感谢您对公司的关注。公司2024年员工持股计划共持有5,116,105股公司股票，根据公司2025年第三季度报告（截至2025年9月30号），为公司第8大股东。祝您投资愉快。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011200021649.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300723","BK0239"],"gpt_icon":0},{"id":"2602204345","title":"一品红：2024年员工持股计划第一个解锁期解禁股票并未减持","url":"https://stock-news.laohu8.com/highlight/detail?id=2602204345","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602204345?lang=zh_cn&edition=full","pubTime":"2026-01-09 11:48","pubTimestamp":1767930486,"startTime":"0","endTime":"0","summary":"证券之星消息，一品红(300723)01月08日在投资者关系平台上答复投资者关心的问题。投资者提问：请问贵公司股权激励第一期解禁的股票，又进入二级市场了吗？为什么占比达到了1%不进行公告？一品红回复：尊敬的投资者您好，感谢您对公司的关注。截止2026年1月8日，公司2024年员工持股计划第一个解锁期解禁股票并未减持股票。祝您投资愉快。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010900015896.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300723"],"gpt_icon":0},{"id":"2602212392","title":"股市必读：一品红（300723）1月8日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2602212392","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602212392?lang=zh_cn&edition=full","pubTime":"2026-01-09 02:49","pubTimestamp":1767898148,"startTime":"0","endTime":"0","summary":"截至2026年1月8日收盘，一品红报收于36.02元，上涨1.78%，换手率2.82%，成交量11.77万手，成交额4.26亿元。董秘最新回复投资者： 董秘，您好！2021年5月，公司参股投资了专注于PROTAC领域的创新药研发企业分迪药业，其一家专注于“靶向蛋白降解剂-分子胶”创新药物研发的公司，主要致力于治疗癌症和病毒感染性疾病的分子胶创新药的开发。达歌生物已与武田、默沙东达成研发合作。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010900001535.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300723","BK0239"],"gpt_icon":0},{"id":"2601355001","title":"一品红：布局分子胶领域投资分迪药业和达歌生物","url":"https://stock-news.laohu8.com/highlight/detail?id=2601355001","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601355001?lang=zh_cn&edition=full","pubTime":"2026-01-08 15:30","pubTimestamp":1767857456,"startTime":"0","endTime":"0","summary":"据悉贵公司同时参与分迪药业和达歌生物的融资，且两家公司同处于“分子胶”这个赛道，背后的投资逻辑是什么？2021年5月，公司参股投资了专注于PROTAC领域的创新药研发企业分迪药业，其一家专注于“靶向蛋白降解剂-分子胶”创新药物研发的公司，主要致力于治疗癌症和病毒感染性疾病的分子胶创新药的开发。达歌生物已与武田、默沙东达成研发合作。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010800018977.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300723"],"gpt_icon":0},{"id":"2601173814","title":"股市必读：一品红(300723)股东户数2.65万户，较上期增加30.22%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601173814","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601173814?lang=zh_cn&edition=full","pubTime":"2026-01-07 01:43","pubTimestamp":1767721390,"startTime":"0","endTime":"0","summary":"截至2026年1月6日收盘，一品红报收于35.89元，上涨0.14%，换手率2.38%，成交量9.95万手，成交额3.57亿元。来自：截至2025年12月31日，公司股东户数达2.65万户，较前一期增长30.22%，户均持股数量下降至1.7万股。股本股东变化股东户数变动近日一品红披露，截至2025年12月31日公司股东户数为2.65万户，较11月30日增加6154.0户，增幅为30.22%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010700000781.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300723"],"gpt_icon":0},{"id":"2601007217","title":"一品红（300723）披露关于回购公司股份的进展公告，1月5日股价上涨6.83%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601007217","media":"证券之星","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601007217?lang=zh_cn&edition=full","pubTime":"2026-01-05 18:00","pubTimestamp":1767607237,"startTime":"0","endTime":"0","summary":"截至2026年1月5日收盘，一品红报收于35.84元，较前一交易日上涨6.83%，最新总市值为161.89亿元。该股当日开盘33.53元，最高36.15元，最低33.2元，成交额达5.52亿元，换手率为3.75%。近日，一品红发布关于回购公司股份的进展公告。公告显示，公司于2025年12月15日召开董事会，审议通过回购公司股份方案，拟使用自有资金及/或自筹资金以集中竞价方式回购A股股份，用于维护公司价值及股东权益。回购实施符合相关规定，后续将根据市场情况继续推进回购。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010500027218.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300723"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1771963584692,"stockEarnings":[{"period":"1week","weight":-0.0138},{"period":"1month","weight":-0.0981},{"period":"3month","weight":-0.387},{"period":"6month","weight":-0.5036},{"period":"1year","weight":0.6699},{"period":"ytd","weight":-0.0215}],"compareEarnings":[{"period":"1week","weight":0.0087},{"period":"1month","weight":-0.0045},{"period":"3month","weight":0.0655},{"period":"6month","weight":0.0712},{"period":"1year","weight":0.2207},{"period":"ytd","weight":0.0374}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"一品红药业集团股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"30475人(较上一季度增加14.93%)","perCapita":"13705股","listingDate":"2017-11-16","address":"广东省广州市黄埔区广州国际生物岛寰宇一路27号云润大厦17层","registeredCapital":"45169万元","survey":" 一品红药业集团股份有限公司的主营业务是药品的研发、生产和销售。公司的主要产品是化学药(含原料药和制剂)、特色中成药等。公司曾先后获得中国化药研发综合实力百强企业、中国创新力医药企业100强和中国化药企业百强企业等荣誉称号，是广州生物医药产业链的链主企业。","listedPrice":17.05},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"一品红(300723)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供一品红(300723)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"一品红,300723,一品红股票,一品红股票老虎,一品红股票老虎国际,一品红行情,一品红股票行情,一品红股价,一品红股市,一品红股票价格,一品红股票交易,一品红股票购买,一品红股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"一品红(300723)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供一品红(300723)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}